DOCSLIB.ORG

Transforming Pharma to Deliver Sustainable Long-Term Growth /// March 10-11, 2021 Cautionary Statements Regarding Forward-Looking Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transforming Pharma to Deliver Sustainable Long-Term Growth /// March 10-11, 2021 Cautionary Statements Regarding Forward-Looking Information Transforming Pharma to Deliver Sustainable Long- term Growth /////////// Capital Markets Day March 10-11, 2021 Stefan Oelrich President of the Pharmaceuticals Division Marianne De Backer Head of Strategy and BD&L Pharmaceuticals Christian Rommel Head of R&D Pharmaceuticals 1 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com/. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments. 2 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 1 Overview Pharma: Focused on Therapeutic Areas with High Unmet Needs Sales development EBITDA margin development Sales by region In €m In %, before special items In %, in 2020 17,962 16,420 16,847 16,746 17,243 North 34.9 America 22 33.9 33.4 32.0 32.6 40 EMEA Latin 5 America 33 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 Asia / Pacific Therapeutic areas Leading positions in key therapeutic areas Top products In %, based on sales 2020 In €m, based on sales 2020 Cardiovascular Other 4,515 Hematology 10 Hematology 5 2,468 Cardiovascular 37 Retinal Diseases Ophthalmology 14 1,081 9 Women´s Health Oncology 851 9 16 Radiology Radiology Women´s Health 670 3 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 2 Pharma Mark et We are Operating in a Rapidly Changing but Attractive Market Environment Pharma Market Market Dynamics Market Size 20201 Opportunities Japan • Rising life expectancy and increased access to China healthcare systems 7% APAC 8% • Accelerated digital transformation across the 9% value chain • Technological disruption by breakthrough science ~ €1,000bn 52% Americas • Shift from treatment to prevention and potential 24% cure EMEA Challenges Market CAGR 2020-24e2 • Pressure on pricing • Declining R&D productivity 4 - 5% • Increased pressure for value and real-world evidence 1 Source: IQVIA MIDAS MAT Q3-20 2 Source: IQVIA Market Prognosis as of September 2020 4 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 3 Strategy The Transformation of Pharma is Underway New management team focused on improving existing structures and processes Realize full potential of products and pipeline to mitigate LoE impact and return to growth Re-allocate resources and shape financial profile to post LoE future Capitalize and build on investments in breakthrough innovation, espec. C&GT Challenge strategic direction of R&D - enhance focus on external innovation 5 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 3 Strategy Our Transformation is Guided by Five Strategic Focus Areas Strategic Focus Areas Portfolio and Digital Health Cell & Gene Oncology China & US Pipeline Therapy Key Priorities Maximize the value of the current portfolio and manage the loss of exclusivity for Xarelto & Eylea Deliver three new potential blockbusters from late-stage pipeline Build digital health solutions and capitalize on Cell & Gene therapy platform Build an at scale player in oncology in our areas of focus Evolve regional strategies in China and the US to sustain future growth 6 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 4 Xarelto & Eylea Xarelto and Eylea are on Track to Deliver Peak Sales Potential Xarelto Eylea €bn €bn 2.5 2.5 4.5 4.1 2.2 3.6 1.9 3.3 2.9 1.6 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 • Peak sales potential > €5bn • Peak sales potential > €2.5bn • Strongest real-world experience • Leveraging leading market position in retinal diseases • Most comprehensively licensed NOAC • Investigating high-dose formulation • Near-term impact due to Covid-19 7 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 4 Xarelto & Eylea Xarelto´s Loss of Exclusivity Will be Staggered Over Several Years Xarelto´s main patent expirations Xarelto sales by main markets Effective Region Patent USA Duration Other regions China Compound patent 2020 12% 11% Japan Compound patent 2022-2025 Germany Japan 11% Europe Compound patent Q1 2024 11% incl. 6 months pediatric FY 2020 exclusivity 5% France €4.5bn USA Compound patent Q1 2025 11% 6% China incl. 6 months pediatric UK exclusivity Once-daily use patent 2027* 33% Other EMEA *) Litigation settled with all 16 generic defendants. Terms are confidential. As reported for Q3 2020, Unichemis licensed to market a generic version of Xarelto 10/15/20mg beginning in 2027. Official patent expiration in 2034. 8 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 4 Xarelto & Eylea Historic Genericization Patterns of Small Molecules Reveal that the most Pronounced LoE Impact Occurs in the US Standard Units Atorvastatin (Lipitor™) Standard Units Clopidogrel (Plavix™) Valsartan (Diovan™) Standard Units 120% 120% 120% 100% 100% 100% 80% 80% 80% 60% 60% 60% 40% 40% 40% 20% 20% 20% 0% 0% 0% Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year Year 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 • Post LoE, in EU5 and Latin America sales decrease moderately over time while in the US, sales are declining rapidly • Staggered market entry of generics in many European countries • Most Emerging Markets are characterized by private and tender business, reducing relevance of patent expirations Source: IQVIA Data; Standard Unit Volume set to 100% in the year of patent expiration Lipitor, Plavix and Diovan are trademarks of Pfizer, Sanofi and Novartis respectively 9 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 4 Xarelto & Eylea Bayer´s Long-Term Sales Projection Reveals Limited LoE Impact and Return to Sustainable Long-term Growth Value maximization Xarelto LoE Return to sustainable growth Trough 2020 expectedin Sales: €17.2bn Bayer Pharma 2024 Sales Projection Margin1: 35% Market Estimate2 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 EBITDA margin before special items 2 Consolidated estimates from seven major banks as of Jan. 2021 Graphic illustrative 10 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 5 Growth Drivers We Laid The Foundation for Long-term Growth at Pharma Main Building Blocks of Post LoE Growth 1 Late-stage Pipeline Finerenone Elinzanetant in CV & WH (KaNDy NT-814) Oncology Pipeline eg. EGFRexon20 inhib., ATR inhib., TTCs C&GT platform expected to deliver Cell & Gene Therapy significant sales contributions from Platform ~2025 onwards External Innovation >25 BD&L-transactions signed in 2020 and BD&L Enhanced focus on external innovation to replenish pipeline 1 In collaboration with Merck & Co. Inc., Kenilworth, NJ, USA 11 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 Christian Rommel Head of Pharma R&D 12 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 6 R&D A Successfully Matured Late-stage Pipeline May Deliver Three New Potential Blockbusters Nubeqa (Darolutamide)1 Finerenone Elinzanetant AR-Antagonist MR-Antagonist Dual NK 1,3 Receptor-Antagonist • Launched in nmCRPC - global roll- • Significant reduction of renal and • First-in-class oral, non- out underway cardiovascular outcomes in hormonal, once-daily • Differentiated clinical profile - 31% patients with CKD and T2D neurokinin-1,3 receptor OS benefit & favourable safety • Filed in key markets - FDA priority antagonist profile (ARAMIS) review • Promising phase IIb data for the • Prim. completion of phase III trial in • Phase III trials in CKD/T2D treatment of frequent mHSPC with chemo mid-2021e (FIGARO) and in HFm/pEF menopausal symptoms (ARASENS) (FINEARTS-HF) ongoing • Phase III to be initiated in 2021 • New phase III trial in mHSPC • Peak sales potential ≥€1bn • Peak sales potential >€1bn without chemo (ARANOTE) • Peak sales potential ≥€1bn 1 In collaboration with Orion Corporation 13 /// Bay er Capital Markets Day /// Transforming Pharma to Deliver Sustainable Long-term Growth /// March 10-11, 2021 6 R&D Peak-sales Potential of Key Late-stage Pipeline Assets 2018 2021 Peak Sales New: Peak Sales Pipeline Asset Pipeline Asset Potential Elinzanetant Potential Nubeqa1 ≥ €1bn (KaNDy NT-814) Nubeqa1 ≥ €1bn (Darolutamide) (Darolutamide) Finerenone ≥ €1bn Finerenone ≥ €1bn Vitrakvi > €750m Elinzanetant > €1bn (Larotrectinib) (KaNDy NT-814) Aliqopa ≥ €0.5bn (Copanlisib) Launched: Verquvo2 ~ €0.5bn Vitrakvi (Vericiguat) Aliqopa Verquvo2 (Vericiguat) 1 In collaboration with
Load more

Recommended publications
  • Controlling Pregnancy: Fred Lyman Adair and the Influence of Eugenics on the Development of Prenatal Care
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2019 Controlling Pregnancy: Fred Lyman Adair And The nflueI nce Of Eugenics On The evelopmeD nt Of Prenatal Care Florence Hsiao Follow this and additional works at: https://elischolar.library.yale.edu/ymtdl Recommended Citation Hsiao, Florence, "Controlling Pregnancy: Fred Lyman Adair And The nflueI nce Of Eugenics On The eD velopment Of Prenatal Care" (2019). Yale Medicine Thesis Digital Library. 3504. https://elischolar.library.yale.edu/ymtdl/3504 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. Controlling Pregnancy: Fred Lyman Adair and the Influence of Eugenics on the Development of Prenatal Care A Thesis Submitted to the Yale University School of Medicine In Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine By Florence Hsiao Class of 2019 Abstract This thesis examines the development of prenatal care in the United States in the early 1900s by focusing on the life and career of Fred Lyman Adair who, as an obstetrician and eugenicist, played a significant role in shaping prenatal care into what it is today. Although prenatal care was a product of infant welfare activists and public health officials, obstetricians like Adair who struggled to establish obstetrics as a legitimate specialty, saw an opportunity in prenatal care to pathologize pregnancy and elevate their specialty.
    [Show full text]
  • An Overview: Innovation in Plant Breeding
    An Overview: Innovation in Plant Breeding Modern plant breeding blends traditional ways of developing crops with the latest in science and technology to achieve improved crops – enabling more choices for both farmers and consumers, and producing crops that can better cope with evolving pests, diseases and a changing climate. The Basics What: The simplest definition of plant breeding is crossing two plants Most of the fruits, vegetables, and to produce offspring that share the best characteristics of the two grains that we eat today are the parent plants. Breeders make crosses then select which offspring to advance in the pipeline based on their desired characteristics. result of generations of plant breeding. About 5,000 years ago, Why: Even the earliest farmers understood that, in order to survive, watermelons were only they needed plant varieties specifically adapted to their environmental conditions and cultivated to produce the best foods to nourish their 2 inches in diameter livestock and communities. and had a bitter taste, vastly How: Through generations of research and discovery, plant breeding has advanced beyond selecting a parent plant simply based on its different from appearance. It now includes an in-depth understanding of plants’ the large, genetic makeup, enabling breeders to better predict which plants will sweet-tasting have the highest probability of success in the field and the grocery fruit we enjoy store before making a cross. today. The Background The earliest farmers were plant breeders who understood the value of identifying crops that showed beneficial characteristics to plant in future seasons. Later, they learned they could cross two plants to develop an even better plant.
    [Show full text]
  • The Debate on the Golden Rice and Its Background
    The Debate on the Golden Rice and its Background A Literature Review Klaus Ammann, [email protected] Dedicated to the inventor and relentless promoter of Golden Rice, Ingo Potrykus Judge GM crops on their properties, not the technique used to make them – and we can start saving lives Editorial help: Vivian Moses, Patrick and Michael Moore 20140615 references numbered with full text links Millions of children die worldwide every year, an untenable situation that is still worsening which needs immediate correction. According to the World Health Organization (1), an estimated 250 million preschool children are vitamin A deficient (= VAD) and it is likely that in VAD areas a substantial proportion of pregnant women are also affected in 2013. Earlier reports (2) make evident that the problems are still growing: (in 2004: 140 million preschool children and more than 7 million pregnant women were suffering from VAD) 2 Preface It is not the intention of the author for this literature compilation on Golden Rice to replace the two websites www.goldenrice.org and www.allowgoldenricenow.org, they contain major information pieces, are well organized and specific information is easy to access. Rather it is the aim here to pull together a set of publications related to the background of the Golden Rice debate. We often are confronted with all kinds of determined opinions about the Golden Rice, Bio-Fortification, Transgenic Plants, Traditional and Organic Agriculture etc. and it is the purpose of this summary to shed light to the background of opinions pro and contra the Golden Rice – on how and why those opinions grow and how they are unfortunately melting down into simplistic slogans.
    [Show full text]
  • View Presentation
    Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva1 Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda
    [Show full text]
  • Bayer Cropscience Contaminates Our Rice
    Bayer e CropScience contaminates our rice greenpeace.org Campaigning for Sustainable Agricultur Greenpeace is an independent global campaigning organisation that acts to change attitudes and behaviour, to protect and conserve the environment and to promote peace. Contents A Contamination Nightmare 3 US Export markets impacted by GE contamination 4 Key dates in the LL rice scandals 5 The situation now 6 LL601 and other Bayer GE rice varieties 7 Should consumers be worried about eating LL rice? 7 Contamination threats 8 Bayer CropScience 9 Rice facts 9 Securing a Healthy Industry - Conclusion and Demands 10 End Notes 11 For more information contact: [email protected] JN 085 Published in October 2007 by Greenpeace International Ottho Heldringstraat 5 1066 AZ Amsterdam The Netherlands Tel: +31 20 7182000 Fax: +31 20 5148151 greenpeace.org Cover image: ©Greenpeace/Novis Bayer CropScience contaminates our rice The following is a summary of events Japan and Korea imposed equally strict testing requirements, surrounding one of the worst cases of genetic followed some months later by the Philippines when engineering contamination of food in history Greenpeace revealed contamination there. Russia and Bulgaria imposed bans on US rice and Mexico, Iraq and and one of the most damaging events in the Canada imposed test and certification requirements on history of the US rice industry. imports. The United Arab Emirates required a GE free guarantee. (5) The devastation has been caused by the multinational company Bayer CropScience - which maintains that the contamination As of July 2007, Greenpeace has identified 30 countries wasn't their fault - it was an 'act of God'.
    [Show full text]
  • Agribusiness and Antitrust: the Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union
    The Global Business Law Review Volume 7 Issue 1 Article 9 7-1-2018 Agribusiness and Antitrust: The Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union Aleah Douglas Cleveland-Marshall College of Law Follow this and additional works at: https://engagedscholarship.csuohio.edu/gblr Part of the Antitrust and Trade Regulation Commons, and the Business Organizations Law Commons How does access to this work benefit ou?y Let us know! Recommended Citation Aleah Douglas, Agribusiness and Antitrust: The Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union, 7 Global Bus. L. Rev. 156 (2018) available at https://engagedscholarship.csuohio.edu/gblr/vol7/iss1/9 This Note is brought to you for free and open access by the Journals at EngagedScholarship@CSU. It has been accepted for inclusion in The Global Business Law Review by an authorized editor of EngagedScholarship@CSU. For more information, please contact [email protected]. AGRIBUSINESS AND ANTITRUST: THE BAYER-MONSANTO MERGER, ITS LEGALITY, AND ITS EFFECT ON THE UNITED STATES AND EUROPEAN UNION ALEAH DOUGLAS I. INTRODUCTION……………………………………………………………………... 157 II. BACKGROUND…………………………………………………………………….....158 A. A Review of the Bayer-Monsanto Merger………………………….…………... 158 B. United States Antitrust Laws…………………………………………………… 161 1. The Applicable Laws……………………………………………………. 161 2. Problems and Antitrust Violations……………………………………… 166 3. American Agribusiness…………………………………………………. 167 C. European Union Antitrust Laws……………………………………………….. 172 1. The European Union……………………………………………………. 172 2. The Applicable Laws………………………………….………………… 172 3. Problems and Antitrust Violations……………………….………....…... 174 4. European Union Agribusiness…………….…………………………….. 176 D. Illegality and Detriment …………………………………….…………………. 178 III. CONCLUSION……………………………………………………………………....... 180 ABSTRACT This note examines the current and historical antitrust laws of the United States and the European Union as they relate to the currently pending merger between Bayer and Monsanto.
    [Show full text]
  • Case M.8851 – BASF / BAYER DIVESTMENT BUSINESS
    EUROPEAN COMMISSION DG Competition Case M.8851 – BASF / BAYER DIVESTMENT BUSINESS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Decision on the implementation of the commitments - Purchaser approval Date: 07/11/2018 EUROPEAN COMMISSION Brussels, 07.11.2018 C(2018) 7488 final PUBLIC VERSION In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case M.8851 – BASF / Bayer Divestment Business Approval of Syngenta Crop Protection AG as purchaser of the [NSH line of research 1 remedy package], following your letter of 13 September 2018 and the Trustee’s opinion of 18 October 2018 FACTS AND PROCEDURE 1. By decision of 30 April 2018 (the "Decision") pursuant to Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation (EC) No 139/2004 of 20 January 2004 on the control of concentrations between undertakings1 (the "Merger Regulation"), the Commission declared the acquisition of assets of Bayer Aktiengesellschaft (the "Bayer Divestment Business") by BASF SE ("BASF") compatible with the internal market subject to full compliance with the commitments submitted by BASF, which were annexed to the Decision (the "Commitments"). 2. In particular, pursuant to the Decision, the Commitments provide that in order to address the serious doubts raised by the combination of BASF's and the Bayer Divestment Business' activities in certain nematicide markets as well as in weed management innovation, BASF would divest (i) its Trunemco nematicide (the "Trunemco Assets") as well as, separately, (ii) a package of data and intellectual 1 OJ L 24, 29.01.2004, p.
    [Show full text]
  • The Bio Revolution: Innovations Transforming and Our Societies, Economies, Lives
    The Bio Revolution: Innovations transforming economies, societies, and our lives economies, societies, our and transforming Innovations Revolution: Bio The The Bio Revolution Innovations transforming economies, societies, and our lives May 2020 McKinsey Global Institute Since its founding in 1990, the McKinsey Global Institute (MGI) has sought to develop a deeper understanding of the evolving global economy. As the business and economics research arm of McKinsey & Company, MGI aims to help leaders in the commercial, public, and social sectors understand trends and forces shaping the global economy. MGI research combines the disciplines of economics and management, employing the analytical tools of economics with the insights of business leaders. Our “micro-to-macro” methodology examines microeconomic industry trends to better understand the broad macroeconomic forces affecting business strategy and public policy. MGI’s in-depth reports have covered more than 20 countries and 30 industries. Current research focuses on six themes: productivity and growth, natural resources, labor markets, the evolution of global financial markets, the economic impact of technology and innovation, and urbanization. Recent reports have assessed the digital economy, the impact of AI and automation on employment, physical climate risk, income inequal ity, the productivity puzzle, the economic benefits of tackling gender inequality, a new era of global competition, Chinese innovation, and digital and financial globalization. MGI is led by three McKinsey & Company senior partners: co-chairs James Manyika and Sven Smit, and director Jonathan Woetzel. Michael Chui, Susan Lund, Anu Madgavkar, Jan Mischke, Sree Ramaswamy, Jaana Remes, Jeongmin Seong, and Tilman Tacke are MGI partners, and Mekala Krishnan is an MGI senior fellow.
    [Show full text]
  • REFERENCE DOCUMENT Including the Sustainable Development Report Contents
    2015 REFERENCE DOCUMENT Including the Sustainable Development Report Contents Key Figures 2 1 Management Report 9 4 Financial statements 199 History of the Air Liquide Group 10 Consolidated fi nancial statements 201 Activities and risk factors 15 Statutory accounts of the parent company 275 2015 Performance 32 Investment cycle and fi nancing strategy 45 Innovation 53 Strategy and outlook 62 5 Annual General Meeting 2016 297 Board of Directors’ Report on the resolutions presented to the 2016 Combined Shareholders’ 2 2015 Corporate Social Responsibility Meeting 298 and Sustainable Development Report 65 Resolutions presented for the approval of the Combined Shareholders’ Meeting – Introduction 66 May 12, 2016 307 Our 2015 Social and Environmental Contribution 67 Statutory Auditors’ Reports 327 Environmental, social and governance (ESG) report 69 Reporting methodology 113 Independent verifi er’s report 115 Appendix 118 6 Additional information 339 Share capital 340 General information 346 3 Corporate governance 119 Trade payables 356 Factors that may have an impact in the event Management and control 120 of a takeover bid 357 Report from the Chairman of the Board of Directors 123 Person responsible for the Reference Document 359 Remuneration of the Executive Offi cers and Directors Cross-reference table for the Reference Document 360 of L’Air Liquide S.A. 147 Cross-reference table for the Annual Financial Report 364 Statutory Auditors’ Report 174 Cross-reference table for the Management Report 365 Transactions involving Company shares performed
    [Show full text]
  • Askbio Announces IND for LION-101, a Novel Investigational AAV Gene
    AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA -- LGMD2I/R9 is a Rare Form of Muscular Dystrophy with No Approved Therapies – -- First-in-Human Phase 1/2 Clinical Study Expected to Begin Dosing in 1H 2022 – Research Triangle Park, N.C. – May 25, 2021 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that the U.S. Food & Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for LION-101 to proceed in a Phase 1/2 clinical study. LION-101 is a novel recombinant adeno-associated virus (rAAV) based vector being developed as a one-time intravenous infusion for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). LION-101 will be evaluated in a first-in-human Phase 1/2 multicenter study to evaluate a single intravenous (IV) infusion in adult and adolescent subjects with genotypically confirmed LGMD2I/R9. AskBio plans to initiate dosing for the LION-101 Phase 1/2 clinical study in the first half of 2022. “In preclinical mouse models, LION-101 therapy demonstrated both dose-dependent efficacy and tolerability, providing a clear approach to study this novel AAV vector in first-in-human trials,” said Katherine High, MD, President, Therapeutics, AskBio. “Currently there are no approved therapies for LGMD2I/R9, and with limited treatment options that only address symptoms of the disease, the patient burden is profound.
    [Show full text]
  • Euronext Single Stock Dividend Futures: the Widest Choice of Contracts
    DIVIDEND DERIVATIVES: PLAY THE DIVIDEND FIELD WITH EURONEXT EURONEXT SINGLE STOCK DIVIDEND FUTURES: THE WIDEST CHOICE OF CONTRACTS September 2019 EURONEXT SSDFS: THE WIDEST CHOICE OF CONTRACTS 1st Dividend Exchange by number of contracts Number of contracts per country of underlying Number Number of SSDFs Underlyings ▪ Euronext began developing the range in of SSDFs only on Euronext Italy 24 11 January 2015 and regularly issues contracts Germany 27 0 to satisfy the needs of end-users Netherlands 23 9 ▪ We have nearly 300 SSDF contracts tradable Belgium 15 14 with the most diversified underlyings from Portugal 3 3 France 47 7 across Europe and the USA. Ireland 1 0 ▪ Investors can access dividend contracts on UK 36 10 new underlyings, as a total of 117 SSDFs are Spain 22 10 only available at Euronext exclusively. USA 57 36 Finland 7 2 Sweden 13 12 Norway 2 2 Switzerland 18 0 Austria 1 1 │ 2 INTRODUCTION OF SEMI-ANNUAL MATURITIES Euronext introduced semi-annual maturities on a range of Single Stock Dividend Futures listed on the Paris Derivatives Market, which offer new trading opportunities to market participants by helping them target dividend distributions more accurately on most traded names (see below). For these underlyings, the maturities available are 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months. UNDERLYING ISIN CODE TRADING SYMBOL 1 Sanofi FR0000120578 SA8 2 BNP Paribas FR0000131104 BN8 3 AXA FR0000120628 CS8 4 Air Liquide FR0000120073 AI8 5 Orange SA FR0000133308 FT8 6 Vinci SA FR0000133308 DG8 7 LVMH FR0000121014 MC8 8 ENGIE
    [Show full text]
  • From Bayer and BASF with Double Standards 2 Global Market for Pesticides
    Hazardous Pesticides from Bayer and BASF —a global trade with double standards 2 Global market for pesticides Bayer and BASF in the global pesticide market The world leading pesticide manufacturers are show the double standards in the global market for increasingly subject to criticism for products that are pesticides. Together, the two companies market at least hazardous to health and the environment, with one 28 active ingredients in South Africa and Brazil that difficult-to-pronounce active ingredient entering are not approved in the EU—whereas BASF sells 13 at a public discourse after another—such as, glyphosate, minimum, Bayer sells at least 15. Seven of these active neonicotinoids, and chlorpyrifos. What has so far ingredients (five from Bayer, two from BASF) were either gone unnoticed, however, are the double standards rejected following the review process or their approval that companies like Bayer and BASF use to market was explicitly revoked by the EU. A total of 14 active their pesticides globally. That is, German pesticide ingredients from Bayer and BASF can be found on the manufacturers produce a number of active ingredients PAN list of highly hazardous pesticides, six from BASF that are not approved in the European Union (EU) and and eight from Bayer. The Bayer AG sells the hazardous export them to countries in the Global South where active ingredients carbendazim and propineb, and at the regulations governing pesticide approval are often BASF one can find chlorfenapyr, cyanamide, glufosinate weaker than in the EU. Research by the Pesticide Action and saflufenacil, for example (for more detailed Network (PAN)1 has shown that 62 active ingredients information, see Appendices 1 and 2).
    [Show full text]